Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Coherus BioSciences

CHRS

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Coherus BioSciences. A complete text table follows the diagram.

Coherus BioSciences Immunology Therapeutics Platform

Biosimilar and immunology medicines support Coherus BioSciences' healthcare platform.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001104659-26-058703
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

The operating total is tied to the filing; the destination is an editorial label for the disclosed business engine, with no invented segment allocation.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The flow begins with the filing-reported operating total and names the company-specific engine described in the filing.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Reported operating total	1	$68.8M	Directly reported in the downloaded 10-Q
immunology therapeutics platform	2	$68.8M	Biosimilar and immunology medicines support Coherus BioSciences' healthcare platform.

Financial flows · Millions of USD
From	To	Value
Reported operating total	immunology therapeutics platform	$68.8M